Immune check-point in cervical cancer
- PMID: 30097236
- DOI: 10.1016/j.critrevonc.2018.06.006
Immune check-point in cervical cancer
Abstract
Despite different treatment strategies, locally advanced cervical cancer (CC) persists as one of the most incurable cancers among women worldwide. In fact, this setting of patients are at high risk of persistent and recurrent disease. In recent years, researches have investigated immune check-point inhibitors in hopes of determining improved response to therapy with prolongation of survival. We reviewed the published literature and conference proceedings and presented pivotal trials supporting immune check-point inhibitors use in the treatment of CC.
Keywords: CTLA-4; Cervical cancer; Immune check-point; Immunotherapy; Ipilimumab; Nivolumab; PD-1; Pembrolizumab.
Copyright © 2018 Elsevier B.V. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials